Group 1 - The stock of Anbiping (688393) has a comprehensive score of 51.00, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 28.47 yuan, 5-day main cost at 28.76 yuan, 20-day main cost at 29.46 yuan [1] - The stock has experienced 2 instances of hitting the upper limit and no instances of hitting the lower limit in the past year [1] Group 2 - Short-term resistance is at 29.54 yuan, while short-term support is at 27.68 yuan [2] - The market is currently indecisive, awaiting direction from the main funds, with the mid-term trend also unclear [2] - The K-line pattern indicates a potential upward movement, with various signals suggesting different market conditions [2] Group 3 - On July 3, 2025, the net inflow of main funds was 423.99 million yuan, accounting for 9% of the total transaction volume [2] - Large orders saw a net inflow of 417.98 million yuan, while retail investors experienced a net outflow of 17.93 million yuan [2] - Related industry sectors include medical devices (0.43%), in vitro diagnostics (0.82%), and internet healthcare (0.73%) [2]

41.28分综合得分 偏弱 趋势方向 主力成本分析 29.13 元 当日主力成本 时间: 2025年5月23日星期五 安必平688393 29.43 元 5日主力成本 30.72 元 20日主力成本 33.62 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 2次 跌停 0 次 技术面分析 30.99 短期压力位 28.80 短期支撑位 33.13 中期压力位 28.80 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★长上影★ 表明行情上档压力沉重,升势受阻 资金流数据 2025年05月23日的资金流向数据方面 主力资金净流入1556.09万元 占总成交额13% 超大单净流入913.75万元 大单净流入642.34万元 散户资金净流出268.65万 关联行业/概念板块 医疗器械 0.25%、体外诊断 0.31%、医疗器械概念 -0.10%、互联医疗 -0.06%等 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并 ...